Get the Stockscreener App
0.5468
2.93%
0.0174
Femasys Inc stock is traded at $0.5468, with a volume of 263.54K.
It is up +2.93% in the last 24 hours and up +0.91% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$0.5294
Open:
$0.5146
24h Volume:
263.54K
Relative Volume:
0.27
Market Cap:
$32.53M
Revenue:
$2.06M
Net Income/Loss:
$-19.80M
P/E Ratio:
-0.7591
EPS:
-0.7203
Net Cash Flow:
$-20.12M
1W Performance:
-3.49%
1M Performance:
+0.91%
6M Performance:
+47.99%
1Y Performance:
-63.91%
1-Day Range:
$0.5141
$0.5468
1-Week Range:
$0.4838
$0.5912
52-Week Range:
$0.3067
$1.7599
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.5468 | 31.50M | 2.06M | -19.80M | -20.12M | -0.7203 |
|
ISRG
Intuitive Surgical Inc
|
501.81 | 176.65B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.24 | 49.56B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
84.01 | 40.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
258.95 | 37.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
43.16 | 36.02B | 28.43B | 1.16B | 1.26B | 1.4457 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
Lake Street initiates Femasys stock coverage with buy rating - Investing.com
FEMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FEMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FEMY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health - TipRanks
New non-surgical permanent birth control clears key global quality hurdle - Stock Titan
Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - Bitget
Sentiment Watch: Is Femasys Inc stock undervalued right nowJuly 2025 Setups & Low Risk Investment Opportunities - baoquankhu1.vn
Femasys receives CPT code approval for infertility treatment By Investing.com - Investing.com India
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Trend Review: Can Femasys Inc benefit from deglobalization2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Femasys receives CPT code approval for infertility treatment - Investing.com UK
AMA procedure code supports new infertility option for over 10M US women - Stock Titan
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - Bitget
Femasys (FEMY) CEO awarded 729,000 RSUs vesting through 2027 - Stock Titan
Femasys (NASDAQ: FEMY) CFO receives 342,000 restricted stock units - Stock Titan
Femasys (FEMY) CTO reports common stock and option holdings in Form 3 - Stock Titan
How cyclical is Femasys Inc.’s revenue streamJuly 2025 News Drivers & Technical Pattern Based Buy Signals - mfd.ru
Femasys : Shareholder Update – 2025 in Review - marketscreener.com
Can Femasys Inc. sustain its profitabilityJuly 2025 Weekly Recap & Risk Managed Investment Strategies - mfd.ru
Forecast Cut: What dividend growth rate does Femasys Inc offerMarket Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Femasys stock rises on new distribution partnership in Switzerland By Investing.com - Investing.com Australia
Femasys expands European presence with Swiss distribution deal By Investing.com - Investing.com Nigeria
Femasys Inc. Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - marketscreener.com
Femasys stock rises on new distribution partnership in Switzerland - Investing.com
Femasys expands European presence with Swiss distribution deal - Investing.com
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - The Manila Times
Femasys Inc. Expands European Presence with New Distribution Partnership in Switzerland - Quiver Quantitative
Insider Sell: Is Omega Healthcare Investors Inc subject to activist investor interest2025 Major Catalysts & Smart Investment Allocation Tips - baoquankhu1.vn
Trading Action: Can Femasys Inc sustain its profitabilityTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Femasys Secures Major Order for FemBloc Launch - MSN
Travel Stocks: What is PCARs revenue forecastEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Returns Recap: Does Ares Management Corporation meet Warren Buffetts criteria2025 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Femasys Receives Nasdaq Extension to Regain Listing Compliance - The Globe and Mail
Femasys granted 180-day extension by Nasdaq to meet minimum bid price rule - Investing.com
Femasys Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Stock Recap: Will FUFU benefit from geopolitical trendsCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Sahm
Femasys receives 180-day Nasdaq extension to meet minimum bid price - Investing.com Nigeria
Femasys secures Nasdaq extension to regain bid price compliance - MSN
Femasys Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Requirement - TradingView
Nasdaq gives Femasys more time to fix sub-$1 share price by July 2026 - Stock Titan
Femasys partners with Refuah Health Center to expand FemaSeed fertility treatment - Investing.com Nigeria
Dow Update: Why Femasys Inc stock attracts global investorsTrade Volume Summary & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Femasys partners with Refuah Health Center to expand FemaSeed fertility treatment By Investing.com - Investing.com South Africa
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):